KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Esperion Therapeutics (ESPR) Operating Expenses: 2018-2025

Historic Operating Expenses for Esperion Therapeutics (ESPR) over the last 7 years, with Sep 2025 value amounting to $97.3 million.

  • Esperion Therapeutics' Operating Expenses rose 43.76% to $97.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $333.2 million, marking a year-over-year increase of 19.42%. This contributed to the annual value of $277.9 million for FY2024, which is 2.21% up from last year.
  • As of Q3 2025, Esperion Therapeutics' Operating Expenses stood at $97.3 million, which was up 29.19% from $75.3 million recorded in Q2 2025.
  • In the past 5 years, Esperion Therapeutics' Operating Expenses registered a high of $97.3 million during Q3 2025, and its lowest value of $60.6 million during Q3 2022.
  • Its 3-year average for Operating Expenses is $73.6 million, with a median of $72.9 million in 2023.
  • As far as peak fluctuations go, Esperion Therapeutics' Operating Expenses slumped by 32.49% in 2021, and later skyrocketed by 43.76% in 2025.
  • Over the past 5 years, Esperion Therapeutics' Operating Expenses (Quarterly) stood at $71.0 million in 2021, then dropped by 13.65% to $61.3 million in 2022, then climbed by 21.66% to $74.6 million in 2023, then decreased by 1.45% to $73.5 million in 2024, then soared by 43.76% to $97.3 million in 2025.
  • Its last three reported values are $97.3 million in Q3 2025, $75.3 million for Q2 2025, and $87.1 million during Q1 2025.